BOSTON, December 6, 2022 – The Institute for Clinical and Economic Review (ICER) today published its latest report on Unsupported Price Increases (UPI) of prescription drugs in the United States. Among the top 10 drugs with net price increases in 2021 that had substantial effects on US spending, ICER determined that seven lacked adequate new evidence to support any price increase.
For this year’s report, an additional three therapies were identified that had the highest increases in total population-based spending by the Centers for Medicare and Medicaid Services (CMS) from 2019 to 2020 due to increases in list prices. We needed to examine this earlier time period because of the delay in public availability of data from CMS. The decision to add a review of therapies based solely on their increase in list pricing reflected concerns ICER heard from patient groups that list price changes in Medicare Part B often have large effects on patients even if net prices do not change significantly.
